COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0
COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Submission of Matters to a Vote of Security Holders

COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

Coherus BioSciences, Inc. (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”) on May 22, 2019. On the March 29, 2019 record date, there were 69,338,697 shares of the Company’s common stock outstanding with each such share being entitled to one vote per share.

At the Annual Meeting, 52,673,489 shares of the Company’s common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 10, 2019.

Proposal 1. The Company’s stockholders elected the Class II director nominees below to the Company’s Board of Directors to hold office until the 2022 Annual Meeting of Stockholders or until their successors are elected.

52,588,990    79,451    5,048


About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).